Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer

IBISCO TRIAL is a phase II trial aimed to demonstrate the improvement of pathological complete response (pCR) in Luminal B breast cancer (BC) patients treated with stereotactic radiation therapy (SBRT) as an anticipated boost associated with neoadjuvant chemotherapy (NAC). As a secondary objective, histochemical and molecular analysis of the tumour and the inflammatory microenvironment will be performed.

Trial Details

NCT ID
NCT05673304
Phase
NA
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Status
RECRUITING
Cancer Type
Inflammatory Breast Cancer Breast Cancer
Interventions
  • SBRT anticipated boost
Locations (sample)
  • Bologna, Italy|44.49381,11.33875

Key Eligibility Criteria

  • Luminal B-like BC, cT1-2
  • Indication for neoadjuvant chemotherapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Inflammatory Breast Cancer Breast Cancer Trials on Trialify →